Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > If this stock was pre split

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Feb 10, 2021 10:46am

124 Views

Post# 32524727

RE:RE:RE:If this stock was pre split

crow27 wrote: Dan should make the move to the Nasdaq ASAP. Strike while it's hot. This company is 10x better than when the stock was .70 cents before the split.
Ring that Nasdaq bell Dan and ring it loud and clear.

Right ... now that we are over $6 and if Dan has enough upcoming releases to drive demand (and potential institutional investors - probably happening now) for our stock ... then we are close to going to a US market.

It's all playing out correctly - patiently building to that point.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China